

Tumour heterogeneity: the key advantages of single-cell analysis

**TELLEZ-GABRIEL M.^{1,*}, ORY B.², LAMOUREUX F.²,
HEYMANN M.F.^{2,3,4}, HEYMANN D.^{2,3,4,*}**

¹Laboratorio Hematologia Oncologica y de Transplantes, Institut Investigacions Biomèdiques (IBB) Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona 08025, Spain

²INSERM, UMR 957, Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, Equipe Ligue 2012, University of Nantes, Faculty of Medicine, 44035 Nantes, France

³Department of Oncology and Metabolism, University of Sheffield, Medical School, Beech Hill Road, S10 2RX, Sheffield, UK

⁴European Associated Laboratory, INSERM, University of Sheffield, Sarcoma Research Unit, Medical School, S10 2RX, Sheffield, UK

Running title: Tumour heterogeneity and single-cell analysis

KEY WORDS: heterogeneity, circulating tumour cells, single cells,

*** Corresponding authors:**

Dr Marta Tellez-Gabriel; E-mail: mtellez@santpau.cat

Prof. Dominique Heymann; E-mail: dominique.heyman@sheffield.ac.uk

Abstract

Tumour heterogeneity refers to the fact that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation, and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterogeneity) and within tumours (intra-tumour heterogeneity), and it is caused by genetic and non-genetic factors. The heterogeneity of cancer cells introduces significant challenges in using molecular prognostic markers as well as for classifying patients that might benefit from specific therapies. Thus, research efforts for characterizing heterogeneity would be useful for a better understanding of the causes and progression of disease. It has been suggested that the study of heterogeneity within Circulating Tumour Cells (CTCs) could also reflect the full spectrum of mutations of the disease more accurately than a single biopsy of a primary or metastatic tumour. In the last years many high throughput methodologies have raised for the study of heterogeneity at different levels (i.e.: RNA, DNA, protein, epigenetic events). The aim of the current review is to stress clinical implications of tumour heterogeneity, as well as current available methodologies for their stud with a specific attention to those able to assess heterogeneity at the single cell level.

1. Introduction

In oncology, molecular, cellular and architectural variability are frequently referred to with the term “heterogeneity”, a concept that increases the complexity of the pathogenesis of malignant tumours. In terms of cell phenotype, cell density or cell location, cell heterogeneity can be observed between tumours that occur in the same organ and/or between patients. Inter-tumour heterogeneity leads to the classification of tumour subtypes which can be distinguished by whether or not their molecular profile correlates with their morphologies and expression of specific markers. In addition, tissue variation also occurs within individual tumours (intra-tumour heterogeneity), meaning that tumour cells can have a range of functional properties and can express a number of markers (1, 2). Such heterogeneity is likely to result in tumours adapting to changes in microenvironmental conditions and/or a tool for changing their malignant potential. This in turn will lead to cellular clones with different sets of undetermined hallmarks (1, 3). Tumour heterogeneity has several key clinical impacts: i) it has been associated with acquired drug resistance; and ii) it limits the precision of histological diagnoses and consequently reduces the value of a biopsy.

Ideally, tumour heterogeneity should be monitored over time, and more specifically in relation to therapeutic strategies. However, the invasiveness of biopsies makes it impractical to perform them frequently. The risk of cell dissemination, the cost of the procedures, as well as sometimes the existence of multiple metastases and the time needed must also be taken into consideration. Circulating tumour cells (CTCs) are a potential surrogate for tissue-based cancer and may thus provide the opportunity for monitoring serial changes in tumour biology. Recent progress has made possible accurate and reliable quantification and molecular characterization of CTCs (4, 5). The present review describes different types of heterogeneity, their clinical

implications, and the techniques currently used to analyse them, stressing the methodologies used to detect CTC heterogeneity at the single-cell level.

2. Types of heterogeneity

2.1 – Intra-tumour heterogeneity

Intra-tumour heterogeneity was demonstrated by Fidler and Hart more than 30 years ago in murine models (6). It refers to the existence of distinct subpopulations of cancer cells within tumours, within various metastatic sites, and between metastatic sites and primary foci (7). Furthermore, intra-tumour heterogeneity applies not only to tumour cells, but also to the components of their microenvironment (8). The cancer cell populations detected differ in terms of tumorigenicity, activation of signalling pathways, evasion from antitumour immunity, induction of senescence, production of secreted factors, migration, metastasis, angiogenic capacity, genetic make-up, response to anticancer agents, and activation of metabolic pathways (1, 9, 10). Intra-tumour diversity is thought to develop either due to genetic (epigenetic) disorders in tumour cells themselves, or under the influence of the tumour microenvironment, or in the background of interactions between these factors (11).

Intra-tumour heterogeneity was initially explained by means of the cancer stem-like cell (CSC) or clonal-evolution models (12) shown in Figure 1. The CSC model is a hierarchical model in which only CSCs can generate a tumour, based on their self-renewal properties and high proliferative potential (Figure 1A). In the clonal evolution model, all undifferentiated clonal cells have similar tumorigenic capacity (Figure 1B). Both paradigms for tumour propagation are likely to exist in human forms of cancer, and the two models are not mutually exclusive. Only the CSC model is hierarchical, however (Figure 1C). A new model for cancer development has

emerged recently combining the two models. The result is a mutant cell that initiates a monoclonal disease. This cell exhibited higher chromosomal instability, leading to the emergence of both new clones and the polyclonal disease associated with secondary genetic events, strengthening the heterogeneity of the tumour. Mutant tumour cells with a growth advantage are then selected and expanded, and the cells in the dominant population have a similar potential for regenerating tumour growth (13). Nevertheless, intra-tumour heterogeneity cannot be limited solely to genetic events. Numerous studies, carried out on cell lines considered as having a high degree of genetic homogeneity, have shown that drug responses are also strongly associated with intercellular epigenetic heterogeneity (14). Epigenetic mechanisms are defined by numerous processes, including DNA methylation, post-translational modification of histones, and chromatin remodelling, all of which are essential for genome organisation, gene expression, and cell function (15). The failure of cancer therapies to achieve sustainable therapeutic responses is often attributed to intra-tumour heterogeneity.

2.2. Inter-tumour heterogeneity

Inter-tumour heterogeneity defines differences between tumours of the same origin in different patients. These tumour subtypes have specific individual molecular signatures, different biological behaviours and, as a result, have a differential impact on clinical outcomes (16). Two main mechanisms have been conceptualised to explain inter-tumour heterogeneity: i) genetic or epigenetic mutations occurring within the same target cell and resulting in different tumour phenotypes (Figure 2A); ii) different tumour subtypes arising from distinct cells within the tissue that serve as the cell of origin (Figure 2B). In addition, extrinsic mechanisms may be involved in generating tumour variability, such as stromal heterogeneity (i.e. the existence of different

populations of cancer-associated fibroblasts), the complexity of immune system infiltration into the tumour bulk, or dysregulation of the extracellular matrix (17). All these mechanisms are crucial for determining malignant growth (18).

3. Sources of heterogeneity

Early findings suggested that genetic heterogeneity was a result of treatment pressure (19). However, it has since been proved that genetic differences in cells within the tumour, between different metastases diagnosed simultaneously, and even within the same excised primary or metastatic tumour, can occur in the absence of any intervening treatment (20-22). Phenotypic differences between cells within a tumour are thought to reflect the genetic differences between them. However, tumour cell diversification is not only due to genetic factors, but also to different non-genetic causes such as epigenetic processes, the microenvironment or stochastic mechanisms, all of which can result in this cell heterogeneity. In the following paragraphs we will summarise the different causes of tumour heterogeneity (Figure 3).

3.1. Genetic heterogeneity

Nowell proposed that most neoplasms have their origin in a single cell, and tumour progression results from acquired genetic variability within the original clone making possible sequential selection of more aggressive subpopulations (13). Nowadays it is well-known that tumours consist of multiple different clones and that there are multiple genetic diversification processes for tumour development (23). Importantly, two very recent studies of prostate-cancer metastases have revealed the existence of the cross-seeding concept, that is, the fact that secondary sites can

be seeded by multiple cell populations derived not only from the primary tumour, but also from other metastases (24, 25).

Chromosomal instability is one of the processes that generate variability. The cells capable of escaping from this genetic instability generate a mutational load and genetic diversity. Increased genetic instability is considered to be one of the hallmarks of cancer (26, 27). The number of cell divisions correlates with random mutagenesis events, and thus with genomic analyses. Larger tumour size is usually associated with higher phenotypic variability. Somatic mutations also contribute to tumour heterogeneity as they generate different subclones that are subjected to a selection process for cancer formation (23). The field cancerisation phenomenon is defined as a transformation process that allows genetically changed but histologically normal cells to precede the development of a tumour (28), and it has been described as one of the mechanisms of intra-tumour heterogeneity (29). Although genetic heterogeneity is not likely to be the primary contributor to intra-tumour phenotypic heterogeneity, in general, genetic changes are heritable and, therefore, essential for somatic evolution during tumour progression and the development of therapy resistance.

3.2. Nongenetic heterogeneity

Nongenetic factors are associated with the development of so-called deterministic and stochastic heterogeneities. Stochastic heterogeneity corresponds to differences between genetically identical cells caused by spontaneous modifications to biochemical processes in the cell when deterministic diversity develops (Figure 3). These processes can result in transient drug resistance and can also promote the transition from one deterministic status to another (30). The

formation of intra-tumour deterministic heterogeneity can be caused by changes in the DNA methylation profile (31), variability in the epigenetic landscape (32), the reorganisation of chromatin, variability in gene expression and microRNAs (33), etc. (Figure 3). In cancer, complex internal and external factors induce changes in tumour cells that affect multiple aspects of cellular biology and differentiation status (34). Internal factors include epigenetic modifications, the genetic background and degree of differentiation. MicroRNAs, which regulate gene expression at the transcriptional level by binding to gene promoters, are now believed to play the most important role in generating cellular diversity within a single tumour (35). Phenotypical changes induced by epigenetics are reversible, which makes it more difficult to study the tumour heterogeneity developed by this process.

The tumour microenvironment, including inflammatory cells, hypoxia conditions or the extracellular matrix, is the main external factor that promotes cell diversity by selecting cells adapted to various conditions in the microenvironment (30). The most obvious example is variation in the distances from individual cancer cells to the vasculature, which leads to differential trophic supply and metabolic status of the cancer cells (18). In addition, other stromal cells – including fibroblasts, inflammatory cells, and pluripotent mesenchymal cells – also contribute to the diversified genotypes and phenotypes of cancer cells by secreting cytokines, growth factors, and extracellular matrix (ECM) components (19).

4. Heterogeneity of distant metastases: circulating tumour cells

Inter-tumour heterogeneity, which reflects the differences in DNA and RNA mutational status and protein expression profiles between the primary tumour and metastases, or within a single

tumour, has been widely reported (36-42). This spatial heterogeneity can result in suboptimal treatment. Circulating tumour cells (CTCs) are a largely pure population of tumour-derived cells that originate in the primary tumour and that are the precursors of metastases (43). Several studies support the idea that cellular heterogeneity within CTCs comprehensively reflects the full spectrum of mutations in the primary tumour and metastatic lesions better than a single primary tumour or metastatic biopsy (44-46).

Different studies have shown that CTCs exhibit considerable cell-to-cell diversity (44, 47, 48). It has also been shown that CTC profiles evolve as the disease progresses (49-51). Conventional molecular assays only reflect the signal from the dominant clone or an average signal from all the clones, even though this may not be the most malignant CTC clone. For this reason, single cell analysis may be a solution to this problem. As CTCs are present at extremely low concentrations in a background of peripheral leukocytes, molecular characterisation of CTCs in the blood remains challenging. There are currently many techniques based on a range of parameters that make it possible to enrich CTCs and single CTCs for further characterisation. These techniques include the CellSearch® system (Veridex), which is the only assay for isolating and enumerating CTCs in clinics that has been cleared by the US Food and Drug Administration, or the DEParray™ technology (Silicon Biosystems), the only automated instrument that can identify, quantify, and recover individual cells (5, 53).

Recent findings have identified the importance of CTC clusters in tumour dissemination. Contrary to common belief, Sam H. Au *et al.* demonstrated that grouped CTCs are able to pass through the narrow vessels to reach distant organs (54). This may be a major source of heterogeneity at the metastatic point, and may imply more effort for developing methodologies to isolate and characterise CTC clusters.

5. Clinical implications of tumour heterogeneity

The main reason why cancer treatments fail is that treatment programmes are not designed to address tumour heterogeneity. Most of the methods used to characterise tumours lead to a global overview of the characteristics of the cancer tissue, corresponding to an average picture of all the tumour clones and their microenvironment. The intra- and inter-tumour variations of biomarkers may affect the success of biomarker-driven clinical trials if the biomarker used to both predict the therapeutic response and stratify the patients into subgroups shows spatial variability. In addition, divergent evolution of metastatic tumour cells and different microenvironments at the metastatic sites may contribute to the change in the expression of biomarkers initially identified in the primary tumour (18, 55). Treating metastatic disease based on the biomarkers expressed in the primary tumour may thus be less than optimal. Deciding which mutations are clinically relevant, and developing an easy-to-interpret framework for reporting the results to clinicians, are complex tasks. Better understanding of tumour content and monitoring changes in cell populations during disease progression and treatment will improve both cancer diagnosis and therapeutic design (Figure 4).

It is possible that new targeted therapies introduced into clinical practice will induce temporary benefits until the tumour becomes resistant. Monitoring accumulated genetic or plastic changes in cancer during the patient's treatment might guide selection of the next therapy, or even the addition of a subsequent therapy. Ideally, researchers would obtain multiple regions from each tumour or metastasis in order to capture spatial heterogeneity. Epigenetic and other analyses also need to be performed. Clinical annotation of the samples and phenotypic correlation are essential at each step. At present, medical protocols envisage obtaining biopsies to establish a diagnosis and determine whether the predictive biomarkers are in agreement or

instead present differences between the metastases and primary tumours. However, most metastases are difficult to access, and biopsies are invasive, inconvenient and costly. Obtaining subsequent biopsies is thus almost impossible from a logistic point of view. To overcome these problems, detecting and characterising CTCs might be an excellent alternative.

Studies on CTCs have focused on their prognostic significance, their utility in real-time monitoring of therapies, the identification of therapeutic targets and resistance mechanisms, and understanding the metastatic process (56). Recently it has been shown that molecular characterisation of CTCs is pivotal for increasing the diagnostic specificity of CTCs and their potential as therapeutic targets (58). As shown in several studies, CTCs are heterogeneous (59-63). Single-cell analysis of CTCs has thus been established as the most reliable method. Dynamic changes or transitions in the biomarker status of CTCs may reflect the presence of the selective pressure that can be exerted by therapeutic interventions. Performing serial measurements of the dynamics of the longitudinal biomarkers displayed in CTCs over the course of multiple sequential therapies may provide insight into tumour evolution (64). Furthermore, monitoring temporal CTC heterogeneity may help identify the most effective drugs in individual cancer patients (65, 66); especially those who already have or will soon have tumours that are resistant to anti-cancer treatments. As an example, one of the most studied markers is PIK3CA. It has been shown that somatic mutations in PIK3CA play a crucial role in therapy response in breast cancer. Monitoring the mutational status of the PIK3CA marker may thus improve the success of treatment decisions in these patients (67). Finally, an interesting application for the study of tumour heterogeneity in clinical practice is related to predictive biomarkers of tumour evolution. The existence of spatial and temporal heterogeneity in the expression of diagnostic markers, between cells in the same tumour region or at the same stage of the disease, limits the

success of current predictive biomarkers. Ideally, identifying the drivers or suppressors of genome instability in solid tumours, whose activation or inactivation is required to initiate intra-tumour heterogeneity and diversity, could provide a tractable means of ultimately attempting to limit the evolutionary processes of tumours (3). As an example, a study by Kovacs *et al.* revealed the existence of large-scale genome instability signatures that are characteristic of BRCA1/2-deficient tumours in more than 80% of the osteosarcoma samples analysed (68).

6. Methods for studying tumour heterogeneity

In the following section we will review available methodologies for studying the tumour heterogeneity in tissues and at the single cell level. The table 1 summarizes the main characteristics of these methods.

6.1. Cell heterogeneity in tissues

Assessing heterogeneity in tissue samples has been limited to methods based on *in situ* hybridisation microscopy, such as immunohistochemistry (IHC), immunofluorescence (IF) and fluorescence *in situ* hybridisation (FISH). *In situ* hybridisation techniques make it possible to detect RNA, DNA and protein molecules with high sensitivity in both frozen and formalin-fixed paraffin-embedded (FFPE) tissues (69, 70). These techniques are normally the methods preferred for studying tumour heterogeneity for several reasons: there are many samples available as they are a routine part of diagnostic pathology; they preserve the specificity of the tissue context; and they have been used to investigate tumour traits at the single-cell level. However, these methods suffer from difficulties in terms of quantifying expression levels and comparing results within

and between samples, owing to variable backgrounds and target accessibility. In addition, the main limitation is the use of these techniques for high throughput analysis.

Comparative Genomic Hybridisation array (a-CGH) can be used to map genome-wide copy number variations in FFPE tissues. This technology can also be used to analyse single cells (71, 72). Immuno-FISH identifies genomic imbalances and specific DNA translocations in particular cell subpopulations by combining the hybridisation of probes with the immunodetection of antigenic markers (73). The RNAscope technique (Advanced CellDiagnostics Inc., Hayward, CA) makes it possible to investigate multiple transcripts in the same tissue section at high-resolution (74). New types of mRNA probes have significantly improved analyses and quantification of spatial gene-expression patterns at the single-cell resolution level; this information has been used to identify cells expressing particular mRNAs in specific anatomic areas (69). Recently, Lee *et al.* described new technology for gene expression profiling in intact cells and tissues called Fluorescent *in situ* sequencing (FISSEQ) of RNA (75). Another very recent method is STAR-FISH, a technique based on combining *in situ* PCR and FISH to make possible the simultaneous detection of point mutations and copy number variations at the single-cell level in high quality FFPE samples. The limitations of STAR-FISH include the need for *a priori* knowledge of the mutation to be analysed and the number of fluorophores that can be applied to detect *in situ* PCR products and chromosomal regions (76).

Heterogeneity at the protein level has mainly been investigated by targeted assays, using antibodies for IHC, or after extraction by reverse phase protein array or liquid chromatography. Matrix-assisted laser desorption/ionisation (MALDI) and multiplexed ion beam imaging are performed *in situ* while preserving the morphological characteristics (77). Evaluating multiple markers at the single-cell level is easier to perform using immunofluorescent antibodies, which

are useful for identifying specific signalling pathways in defined cell subpopulations and/or for identifying the topological locations of cell subpopulations within a tumour (78).

6.2. Cell heterogeneity at the single-cell level

As mentioned in the previous sections, single-cell analysis is the most reliable approach for studying tumour heterogeneity. This section briefly summarises the technologies most used today to identify molecular differences at the single-cell level. Advances in Whole Genome Analysis (WGA), Next Generation Sequence (NGS), fluorescence-activated cell sorting (FACS) and other techniques have made it possible to analyse multiple markers in single tumour cells isolated from fresh or fixed primary tumours and metastases (79-82), and attempts have also been made to use these techniques to explore tumour heterogeneity in individual CTCs (44, 62, 83-85), isolated from blood or bone marrow.

6.2.1. Single-cell genomic and transcriptomic analyses

Single-cell technologies have evolved considerably in the area of genome and transcriptome sequencing in the last ten years. The first challenge is obtaining a suspension of viable single cells from complex solid tissues by means of mechanical or enzymatic dissociation, or by using more sophisticated technologies such as laser-capture microdissection (86). Once in suspension, single cells must be isolated by serial dilution, micropipetting, or FACS among others (87). CTCs from whole blood or bone marrow are enriched using methods specifically developed for this purpose and reviewed elsewhere (5, 52). To study DNA heterogeneity, the next step is to

perform WGA, in order to amplify the single-cell genomes and minimise the introduction of artefacts. There are three main WGA methods: i) pure PCR-based amplification (DOP-PCR); ii) isothermal amplification (MDA); and iii) hybrid methods (MALBAC or PicoPLEX), which are the most commonly used. Performing single-cell MDA in microfluidic emulsions seems to markedly improve the uniformity of amplification and decrease contamination. Many groups have had success with this approach (87).

It is thus necessary to define the type of genomic interrogation of the amplified genomes. Depending on the objective of the study, it is possible to query specific loci of interest (either by target-specific amplification using PCR, or target capture through hybridisation) (88); sequence all of the exome (79); or sequence the entire genome, called Whole Genome Sequencing (WGS) (81). This last method provides more information than the other two approaches, such as the single nucleotide variant (SNVs), copy number variants (CNVs), non-coding and structural variants. The counterpart is the high cost. Determining genetic heterogeneity between single cells after WGS is currently achieved by applying model-based clustering, which makes it possible to include false-negative errors (89).

If the aim of the study is to explore transcriptome heterogeneity (Whole Transcriptome Sequencing or WTS), single-cell RNA sequencing methods must be applied. Nowadays, there are many protocols available for RNA sequencing at the single-cell level, Quartz-seq, CEL-seq, STRT-seq, Smart-seq or Drop-Seq are the best known, each one having both advantages and disadvantages (90, 91). A very recent method described by Chen *et.al* is multiplexed error robust FISH (MERFISH), a single-molecule imaging method that allows thousands of RNA species to be imaged in single cells by using combinatorial FISH labelling with encoding schemes capable of detecting and/or correcting errors (92).

Regardless of which single cell analysis is performed, WGS or WTS, and given the high number of technical errors that emerge during the process, the results must be validated, as these technical errors are often interpreted as real biological variations (93). Despite the initial restrictions of the “omics” techniques in the field of CTC research, many studies have now been described using these technologies to investigate heterogeneity in single CTCs. These studies include that by De Luca *et al.*, in which inter- and intra-patient heterogeneity is observed in the mutational status of breast cancer CTCs analysed by NGS (94). In addition, there have been studies comparing CTCs and metastases or primary tumours at the single-cell level, such as the study performed by Jiang *et al.* in which they discovered highly heterogeneous short structural variants of PTEN, RB1, and BRCA2 in all tumour and CTC prostate samples assessed using high-quality WGS (95). Interestingly, Powell *et al.* performed one of the first studies in CTCs focused on single-cell transcriptomes. They used a microfluidic platform (Fluidigm) to perform multiplexed quantitative PCR (qPCR) on 87 cancer genes in different breast cancer samples. Importantly, they found high transcript levels of the genes associated with metastases NPTN, S100A4, S100A9, and with epithelial mesenchymal transition: VIM, TGF β 1, ZEB2, FOXC1, CXCR4 (96). More recently, Lang *et al.* published a study of RNA expression profiling of breast cancer CTCs using cDNA microarrays (97).

Another source of tumour cell heterogeneity is related to epigenetics, including histone modification, and DNA base modifications (such as methylation and hydroxymethylation), as mentioned previously. Robust technologies have been developed to provide genome-wide maps of most epigenetic marks. ChIP-seq, suitable for studying histone marks at the single-cell level, combines chromatin precipitation with next generation sequencing (98). To assess methylation levels, the most comprehensive picture can be obtained from whole-genome bisulphite

sequencing (WGBS) (99), but precipitation techniques (methylated-DNA immunoprecipitation sequencing and methylated-DNA-binding domain sequencing) or reduced-representation bisulphite sequencing (RRBS) (100) are also in use. Illumina's Infinium Human Methylation450 BeadChip platform provides an array-like alternative that has been found to provide acceptable DNA methylation profiles, reducing the DNA-damaging effects of bisulphite treatment (101).

6.2.2. Single-cell proteomic analysis

Fluorescent Activated Cell Sorting (FACS) data makes it possible to identify disrupted expression patterns in the proteins on cells in cancer, as well as to analyse signalling networks (phosphorylation) and their link to the outcome of the disease. The instruments grouped under the term 'flow cytometer' now extend to microfluidics, and miniaturise the components, into lab-on-a-chip devices (102, 103). These instruments set a high standard for very quantitative and high-throughput multiparameter measurements of single-cell attributes (104). Several studies using single-cell phosphorylation analysis by means of flow cytometry, known as phospho-flow, have been performed in cancer, leading to classification of patients into several groups (105), and predicting outcome (106) and drug sensitivity (107).

One of the drawbacks of the flow cytometry analysis is that certain pathways may be sensitive to disruption when cells are taken out of context, leading to changes in the intracellular signalling, and this may thus alter the results of the cell heterogeneity analysis. In whole blood-based assays (i.e. isolating CTCs), this tends to be minimised. Studying proteomics at the single-cell level is also possible with Cytometry time of flight (CyTOF), developed by Tanner *et al.* (108). CyTOF was developed into an imaging tool that can image the localisation of up to 32

proteins at present (and potentially up to 100) with subcellular resolution (109). Briefly, this method is based on tagging antibodies with isotopes not found in cells, staining the cells with those tagged antibodies, and then ionising the sample before passing it into a time-of-flight (TOF) mass spectrometer. Ions have a specific mass range and are quantified with the CyTOF instrument. All isotope signals are integrated for each cell and digitised to create a spreadsheet of cell-by-cell information similar to a flow cytometry data file, but containing much more information. This complexity is reduced thanks to analytical approaches such as SPADE (110). A study performed by Han *et al.* validated the feasibility of this method for the study of single-cell heterogeneity in cancer (111).

Conclusions and future direction

Cancer is a heterogeneous disease, with variations in terms of morphology, immunophenotype and genotype. Analysing conventional genetic profiling on bulk single biopsy tissues is often used today as the standard for evaluating tumours, thus limiting diagnostic and treatment decisions to the region analysed. Profiling of bulk samples may also unravel the phenotypes obtained from previous selective pressures and which are not relevant to the status of the current metastatic disease. Furthermore, different regions of the same tumour can contain signatures for either good or bad prognoses; a single biopsy may thus not be sufficiently representative of the tumour's composition.

Circulating tumour cells (CTCs) can be isolated and interrogated as a potential window into the genetics of a tumour by means of non-invasive sampling, making it possible to evaluate the tumour's temporal heterogeneity during the clinical course of the disease. To overcome the

averaging approach determined by using bulk CTC analysis, single-cell isolation can only be achieved with sophisticated instrumentation, requiring expert operators such as the DEPArray™ system, (Silicon Biosystems, Italy) and time-consuming protocols which can only guarantee the single-cell level on rare occasions (5, 112). CTCs have been used successfully to reveal tumour heterogeneity, and can readily be subjected to dynamic monitoring (113). However, CTCs are present at very low concentrations in peripheral blood, and current studies of CTCs are generally limited to advanced forms of cancer. Not all patients with advanced cancer have detectable CTCs, and only a few studies have detected CTCs in patients with early-stage cancer (114). A considerable proportion of cancer patients diagnosed in the early stages develop distant metastases after surgical removal of the primary tumour, indicating that CTCs are present even during the early stages of cancer. A detection system with analytical sensitivity and capable of demonstrating adequate cell recovery and sampling accuracy is needed to successfully isolate and enrich heterogeneous CTCs.

One of the key questions is to determine to what extent CTCs represent heterogeneity within the primary tumour or metastases. It is possible that the cells detected with the techniques currently available are merely those that were shed and are only the ‘tip of the iceberg’. For example, it is clear that a high number of CTCs detected are associated with poor prognosis, but it is not possible to know if these cells actually have malignant behaviour themselves. Perhaps they are just terminally differentiated cells that merely reflect the presence of more malignant, but uncaptured, cancer cells. These cells do not necessarily represent the biology of the underlying tumour (115). Interestingly, recent data suggest that CTC clusters are able to extravasate through narrow vessels and invade surrounding tissues (54). In this context, cluster CTCs may have greater metastatic potential than individual CTCs, and identifying and isolating

these clusters is a key challenge for the future. Further investigation is needed to both validate this recent discovery and develop new technologies for in-depth study of heterogeneity in CTC clusters (54).

In the last ten years, many new technologies have been developed in order to characterise single-cell heterogeneity at the DNA, RNA or protein level. Some of these technologies are reviewed in Section 6. The methodologies present several disadvantages, such as reduced sensitivity for low expressed genes, small quantities of sample material, amplification biases, technical noise or low throughput, among others. In addition, data mined from single-cell studies must be carefully studied with rigorous computational analyses, which are imperative for distinguishing pre-existing genetic alterations from amplification errors. Improper computation may result in bias and errors in data interpretation, especially in highly heterogeneous samples. Independent analyses from multiple single cells may also be used to reveal repeated and specific mutational patterns, which will be pivotal in distinguishing technical noise from biological signals (93). A complete picture of a cell's state will often require measurements of different parameters in the same cell (i.e. transcriptome, genome, epigenome). Although it is usually possible to perform multiple assays on a bulk sample, this is only possible in certain cases for single-cell measurements (116). Further development of multi-model measurement methods will help understand different sources of heterogeneity in a single cell. A major challenge is new multiplexing strategies that can be used to profile single cells quickly and at a reasonable cost.

It is important to note that the tumour microenvironment itself is also heterogeneous. This microenvironment, which defines an additional barrier or an asset for therapy, is responsible for differently directed selective pressure within the same tumour, changing the evolutionary trajectories of the tumour cells (117). This opens up new areas of research for developing

techniques focusing on regulating the tumour microenvironment in order to control tumour progression. One long-term goal is to move toward tagless, or almost tagless, measurements, in which viable cells are isolated prospectively based on function, gene expression and genotypes and then assayed directly for their tumour-initiating capacity. Techniques that probe the three-dimensional composition (architecture and cell types) of tumours, while minimally disrupting cell biology, are also required to gain more information on cell-type location and its relationship to disease. Currently, the only approaches that are readily available (e.g., green fluorescent proteins or other gene expression–based reporters) require genetic modification of the target cell.

Acknowledgements

This paper was written as a part of a research project which received funding from the Seventh Framework Programme ([FP7/2007-2013]) under grant agreement n°264817 – BONE-NET. This work was supported by the Bone Cancer Research Trust (UK, research project number 144681).

References

1. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. *Cancer Prev Res (Phila)*. 2010;3(11):1361-4.
2. Visvader JE. Cells of origin in cancer. *Nature*. 2011;469(7330):314-22.
3. Fisher R, Puzstai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. *Br J Cancer*. 2013;108(3):479-85.
4. Alix-Panabieres C, Pantel K. [The circulating tumor cells: liquid biopsy of cancer]. *Klin Lab Diagn*. 2014(4):60-4.
5. Gabriel MT, Calleja LR, Chalopin A, Ory B, Heymann D. Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. *Clin Chem*. 2016;62(4):571-81.
6. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. *Science*. 1982;217(4564):998-1003.
7. Hayes DF, Paoletti C. Circulating tumour cells: insights into tumour heterogeneity. *J Intern Med*. 2013;274(2):137-43.
8. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. *Cell*. 2011;147(5):992-1009.
9. Andrechek ER, Nevins JR. Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. *J Mol Med (Berl)*. 2010;88(11):1095-100.
10. Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. *Adv Pharmacol*. 2012;65:335-59.
11. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis GA, Cohen C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study. *Appl Immunohistochem Mol Morphol*. 2010;18(5):433-41.
12. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer*. 2008;8(10):755-68.
13. Nowell PC. The clonal evolution of tumor cell populations. *Science*. 1976;194(4260):23-8.
14. Mazar T, Pankov A, Song JS, Costello JF. Intratumoral Heterogeneity of the Epigenome. *Cancer Cell*. 2016;29(4):440-51.
15. Portela A, Esteller M. Epigenetic modifications and human disease. *Nat Biotechnol*. 2010;28(10):1057-68.
16. Chekhun VF, Demash DV, Nalieskina LA. [Evaluation of biological effects and possible mechanisms of action of static magnetic field]. *Fiziol Zh*. 2012;58(3):85-94.
17. Cassidy JW, Caldas C, Bruna A. Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. *Cancer Res*. 2015;75(15):2963-8.
18. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. *Annu Rev Pathol*. 2006;1:119-50.
19. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. *Lancet Oncol*. 2012;13(4):e178-85.
20. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, et al. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. *Clin Cancer Res*. 2008;14(7):1938-46.
21. Wicha MS. Cancer stem cell heterogeneity in hereditary breast cancer. *Breast Cancer Res*. 2008;10(2):105.
22. Guidi AJ, Berry DA, Broadwater G, Perloff M, Norton L, Barcos MP, et al. Association of angiogenesis in lymph node metastases with outcome of breast cancer. *Journal of the National Cancer Institute*. 2000;92(6):486-92.

23. Greaves M, Maley CC. Clonal evolution in cancer. *Nature*. 2012;481(7381):306-13.
24. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. *Nature*. 2015;520(7547):353-7.
25. Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. *Nat Commun*. 2015;6:6605.
26. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. *Nat Rev Mol Cell Biol*. 2010;11(3):220-8.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646-74.
28. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. *Cancer Cell Int*. 2007;7:2.
29. Lichtenstein AV. Clonal heterogeneity of tumor may be due to continuous influx of newly transformed cells. *Cancer Biol Ther*. 2006;5(10):1263-4.
30. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? *Nat Rev Cancer*. 2012;12(5):323-34.
31. Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. *Nature genetics*. 2014;46(6):607-12.
32. Wilting RH, Dannenberg JH. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. *Drug Resist Updat*. 2012;15(1-2):21-38.
33. Eriksen AH, Andersen RF, Nielsen BS, Sorensen FB, Appelt AL, Jakobsen A, et al. Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. *PLoS one*. 2016;11(6):e0156919.
34. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. *Dev Cell*. 2010;19(5):698-711.
35. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105(5):1608-13.
36. Vermaat JS, Nijman IJ, Koudijs MJ, Gerritse FL, Scherer SJ, Mokry M, et al. Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. *Clin Cancer Res*. 2012;18(3):688-99.
37. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. *J Clin Oncol*. 2012;30(24):2956-62.
38. Siyar Ekinci A, Demirci U, Cakmak Oksuzoglu B, Ozturk A, Esbah O, Ozatli T, et al. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. *J BUON*. 2015;20(1):128-35.
39. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. *J Clin Oncol*. 2012;30(20):2522-9.
40. Mao C, Wu XY, Yang ZY, Threapleton DE, Yuan JQ, Yu YY, et al. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. *Sci Rep*. 2015;5:8065.
41. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, Moreno-Rubio J, de Castro Carpeno J, et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: implications for cancer therapy. *Curr Cancer Drug Targets*. 2012;12(2):124-31.
42. Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. *Oncologist*. 2012;17(7):978-85.
43. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. *Nature medicine*. 2006;12(8):895-904.

44. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. *Cancer Res.* 2013;73(10):2965-75.
45. Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. *Int J Cancer.* 2013;133(1):130-41.
46. Mohamed Suhaimi NA1 FY, Lee DY1, Phyo WM1, Cima I1, Lee EX1, Goh WL2, Lim WY3, Chia KS3, Kong SL4, Gong M4, Lim B4, Hillmer AM4, Koh PK5, Ying JY1, Tan MH6. Non-invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. *Mol Oncol.* 2015.
47. Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. *Proceedings of the National Academy of Sciences of the United States of America.* 2002;99(4):2246-51.
48. Kraus J, Pantel K, Pinkel D, Albertson DG, Speicher MR. High-resolution genomic profiling of occult micrometastatic tumor cells. *Genes Chromosomes Cancer.* 2003;36(2):159-66.
49. Paillet E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, et al. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. *Ann Oncol.* 2015;26(7):1408-15.
50. Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, et al. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. *Ann Oncol.* 2015;26(12):2464-9.
51. Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. *PLoS Biol.* 2014;12(7):e1001906.
52. Alix-Panabieres C, Pantel K. Technologies for detection of circulating tumor cells: facts and vision. *Lab Chip.* 2014;14(1):57-62.
53. Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. *EMBO Mol Med.* 2015;7(1):1-11.
54. Au SH, Storey BD, Moore JC, Tang Q, Chen YL, Javaid S, et al. Clusters of circulating tumor cells traverse capillary-sized vessels. *Proceedings of the National Academy of Sciences of the United States of America.* 2016;113(18):4947-52.
55. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. *Breast Cancer Res.* 2011;13(6):227.
56. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. *Clin Chem.* 2013;59(1):110-8.
57. Gasch C, Pantel K, Riethdorf S. Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells. *Methods Mol Biol.* 2015;1347:221-32.
58. Toss A, Mu Z, Fernandez S, Cristofanilli M. CTC enumeration and characterization: moving toward personalized medicine. *Ann Transl Med.* 2014;2(11):108.
59. Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. *Cancer Lett.* 2013;335(1):225-31.
60. Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z, et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. *Proceedings of the National Academy of Sciences of the United States of America.* 2013;110(52):21083-8.
61. Fernandez SV, Bingham C, Fittipaldi P, Austin L, Palazzo J, Palmer G, et al. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. *Breast Cancer Res.* 2014;16(5):445.

62. Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. *Mol Oncol*. 2015;9(4):749-57.
63. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. *Br J Cancer*. 2012;106(5):939-46.
64. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. *Ann Oncol*. 2015;26(9):1859-65.
65. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. *J Thorac Oncol*. 2013;8(1):45-51.
66. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. *Science*. 2014;345(6193):216-20.
67. Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, et al. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. *Clin Cancer Res*. 2014;20(22):5823-34.
68. Kovac M, Blattmann C, Ribí S, Smida J, Mueller NS, Engert F, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. *Nat Commun*. 2015;6:8940.
69. Itzkovitz S, van Oudenaarden A. Validating transcripts with probes and imaging technology. *Nature methods*. 2011;8(4 Suppl):S12-9.
70. Summersgill B, Clark J, Shipley J. Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. *Nat Protoc*. 2008;3(2):220-34.
71. Fiegler H, Geigl JB, Langer S, Rigler D, Porter K, Unger K, et al. High resolution array-CGH analysis of single cells. *Nucleic acids research*. 2007;35(3):e15.
72. Oostlander AE, Meijer GA, Ylstra B. Microarray-based comparative genomic hybridization and its applications in human genetics. *Clinical genetics*. 2004;66(6):488-95.
73. Park SY, Gonen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. *J Clin Invest*. 2010;120(2):636-44.
74. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. *J Mol Diagn*. 2012;14(1):22-9.
75. Lee JH, Daugharthy ER, Scheiman J, Kalhor R, Ferrante TC, Terry R, et al. Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. *Nat Protoc*. 2015;10(3):442-58.
76. Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. *Nature genetics*. 2015;47(10):1212-9.
77. Setou M, Shrivastava K, Sroyraya M, Yang H, Sugiura Y, Moribe J, et al. Developments and applications of mass microscopy. *Med Mol Morphol*. 2010;43(1):1-5.
78. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. *Annu Rev Pathol*. 2013;8:277-302.
79. Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. *Cell*. 2012;148(5):886-95.
80. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. *Nature*. 2009;461(7265):809-13.
81. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. *Nature*. 2011;472(7341):90-4.
82. Navin N, Hicks J. Future medical applications of single-cell sequencing in cancer. *Genome Med*. 2011;3(5):31.

83. Schoenborn JR, Nelson P, Fang M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. *Clin Cancer Res.* 2013;19(15):4058-66.
84. Thege FI, Lannin TB, Saha TN, Tsai S, Kochman ML, Hollingsworth MA, et al. Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. *Lab Chip.* 2014;14(10):1775-84.
85. Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. *Clin Chem.* 2013;59(1):252-60.
86. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. *Science.* 1996;274(5289):998-1001.
87. Gawad C, Koh W, Quake SR. Single-cell genome sequencing: current state of the science. *Nat Rev Genet.* 2016;17(3):175-88.
88. Gawad C, Koh W, Quake SR. Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics. *Proceedings of the National Academy of Sciences of the United States of America.* 2014;111(50):17947-52.
89. Yeung KY, Fraley C, Murua A, Raftery AE, Ruzzo WL. Model-based clustering and data transformations for gene expression data. *Bioinformatics.* 2001;17(10):977-87.
90. Saliba AE, Westermann AJ, Gorski SA, Vogel J. Single-cell RNA-seq: advances and future challenges. *Nucleic acids research.* 2014;42(14):8845-60.
91. Wen L, Tang F. Single-cell sequencing in stem cell biology. *Genome biology.* 2016;17:71.
92. Chen KH, Boettiger AN, Moffitt JR, Wang S, Zhuang X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. *Science.* 2015;348(6233):aaa6090.
93. Navin NE. Cancer genomics: one cell at a time. *Genome biology.* 2014;15(8):452.
94. De Luca F, Rotunno G, Salvianti F, Galardi F, Pestrin M, Gabellini S, et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. *Oncotarget.* 2016;7(18):26107-19.
95. Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, et al. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. *Oncotarget.* 2015;6(42):44781-93
96. Powell AA, Talasz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. *PLoS one.* 2012;7(5):e33788.
97. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, et al. Expression profiling of circulating tumor cells in metastatic breast cancer. *Breast Cancer Res Treat.* 2015;149(1):121-31.
98. Rotem A, Ram O, Shoshani N, Sperling RA, Goren A, Weitz DA, et al. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. *Nat Biotechnol.* 2015;33(11):1165-72.
99. Farlik M, Sheffield NC, Nuzzo A, Datlinger P, Schonegger A, Klughammer J, et al. Single-cell DNA methylome sequencing and bioinformatic inference of epigenomic cell-state dynamics. *Cell Rep.* 2015;10(8):1386-97.
100. Doherty R, Couldrey C. Exploring genome wide bisulfite sequencing for DNA methylation analysis in livestock: a technical assessment. *Front Genet.* 2014;5:126.
101. Morris TJ, Beck S. Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip (450k) data. *Methods.* 2015;72:3-8.
102. Wlodkowic D, Darzynkiewicz Z. Rise of the micromachines: microfluidics and the future of cytometry. *Methods Cell Biol.* 2011;102:105-25.
103. Werner M, Merenda F, Piguet J, Salathe RP, Vogel H. Microfluidic array cytometer based on refractive optical tweezers for parallel trapping, imaging and sorting of individual cells. *Lab Chip.* 2011;11(14):2432-9.

104. Sun J, Masterman-Smith MD, Graham NA, Jiao J, Mottahedeh J, Laks DR, et al. A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. *Cancer Res.* 2010;70(15):6128-38.
105. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. *Cancer Cell.* 2008;14(4):335-43.
106. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. *Proceedings of the National Academy of Sciences of the United States of America.* 2010;107(29):12747-54.
107. Palazzo AL, Evensen E, Huang YW, Cesano A, Nolan GP, Fantl WJ. Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. *PloS one.* 2011;6(10):e24592.
108. Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. *Anal Chem.* 2009;81(16):6813-22.
109. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, et al. Toward understanding and exploiting tumor heterogeneity. *Nature medicine.* 2015;21(8):846-53.
110. Qiu P, Simonds EF, Bendall SC, Gibbs KD, Jr., Bruggner RV, Linderman MD, et al. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. *Nat Biotechnol.* 2011;29(10):886-91.
111. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. *Cytometry A.* 2015;87(4):346-56.
112. Carpenter EL, Rader J, Ruden J, Rappaport EF, Hunter KN, Hallberg PL, et al. Dielectrophoretic capture and genetic analysis of single neuroblastoma tumor cells. *Front Oncol.* 2014;4:201.
113. Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. *EMBO Mol Med.* 2014;6(11):1371-86.
114. Murlidhar V, Ramnath N, Nagrath S, Reddy RM. Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection. *Cancers (Basel).* 2016;8(7).
115. Martelotto LG, Ng CK, Piscuoglio S, Weigelt B, Reis-Filho JS. Breast cancer intra-tumor heterogeneity. *Breast Cancer Res.* 2014;16(3):210.
116. Dey SS, Kester L, Spanjaard B, Bienko M, van Oudenaarden A. Integrated genome and transcriptome sequencing of the same cell. *Nat Biotechnol.* 2015;33(3):285-9.
117. Gerdes MJ, Sood A, Sevinsky C, Pris AD, Zavodszky MI, Ginty F. Emerging understanding of multiscale tumor heterogeneity. *Front Oncol.* 2014;4:366.

Figure and table legends

Figure 1: Two models for tumour heterogeneity and propagation. **A)** In the cancer stem cell (CSC) model, only the CSCs can generate a tumour, based on their self-renewal properties and enormous proliferative potential. **B)** In the clonal evolution model, all undifferentiated cells have similar tumorigenic capacity. **C)** Both tumour maintenance models may underlie tumorigenesis. Initially, tumour growth is driven by a specific CSC (CSC1). With tumour progression, another, distinct, CSC (CSC2) may arise as a result of clonal evolution in CSC1. This may be a result of the acquisition of an additional mutation or epigenetic modification. CSC2 is more aggressive and becomes dominant, driving tumour formation. (Adapted from Jane E. Visvader & Geoffrey J. Lindeman)

Figure 2: Two models of inter-tumoral heterogeneity. **A)** In the genetic and epigenetic mutation model, mutations primarily determine the phenotype of the tumour. For this reason, different mutations result in different tumour subtypes. **B)** In the cell-of-origin model, different cell populations in the lineage hierarchy are used as the cells of origin for the different cancer subtypes.

Figure 3. Development factors for tumour heterogeneity. This diagram shows the genetic and non-genetic mechanisms that occur in tumour cells enhancing genome instability and leading to both increased clonal diversity, and the development of genetic, phenotypic and epigenetic heterogeneity. Solid arrows indicate strict regularities and dotted arrows indicate possible relations.

Figure 4. Effects of tumour heterogeneity on the predictive value of biomarkers. Cancer diagnosis is commonly based on a biopsy **(1)** that contains only a small fraction of tumour and may thus not be representative of all the subclones (cells in different colours). The first line treatment can be successful in eliminating dominant clones **(2)**, but resistant clones are selected and drive disease progression **(3)**. Metastases can develop from primary tumour cells, or from clones that survive the initial therapy. Therefore, the clonal composition of metastatic lesions may be completely different from that of the primary tumour sample, and treatments based on the initial diagnostic sample may be suboptimal for the treatment of metastatic disease **(4)**. New diagnosis after a relapse must be made before applying a second line treatment (dashed-red lines) **(5)**. (Adapted from Almendro *et al.*)